BioNTech SE (BNTX) Cost of Revenue (2018 - 2025)
BioNTech SE (BNTX) posted Cost of Revenue of $388.0 million for Q4 2025, up 123.78% sequentially from $173.4 million in Q3 2025, and up 49.11% YoY from $260.2 million in Q4 2024.
BioNTech SE (BNTX) Cost of Revenue (2018 - 2025) Analysis & Trends
BioNTech SE has reported Cost of Revenue for 8 years, with the latest figure at $388.0 million in Q4 2025.
- Quarterly Cost of Revenue rose 49.11% year-over-year to $388.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $736.0 million (up 25.75% YoY) and the FY2025 annual result came in at $725.1 million, up 25.36% from the prior year.
- Cost of Revenue climbed to $388.0 million in Q4 2025 per BNTX's latest filing, from $173.4 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $1.5 billion in Q1 2022 and troughed at $1428.6 in Q3 2021.
- A 5-year average of $359.9 million and a median of $190.0 million in 2023 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 4316954798549969.5% in 2021, down 100.0% in 2021.
- Over 5 years, Cost of Revenue stood at $667.2 million in 2021, then sank by 71.94% to $187.2 million in 2022, then increased by 2.93% to $192.7 million in 2023, then jumped by 35.03% to $260.2 million in 2024, then jumped by 49.11% to $388.0 million in 2025.
- According to Business Quant data, Cost of Revenue over the past three periods registered $388.0 million, $173.4 million, and $86.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 387.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 387.98 Mn |
| Dec 31, 2025 | 387.98 Mn |
| Sep 30, 2025 | 173.37 Mn |
| Sep 30, 2025 | 173.37 Mn |
| Jun 30, 2025 | 86.48 Mn |
| Jun 30, 2025 | 86.48 Mn |
| Mar 31, 2025 | 88.15 Mn |
| Mar 31, 2025 | 88.15 Mn |
| Dec 31, 2024 | 260.20 Mn |
| Dec 31, 2024 | 260.20 Mn |
| Sep 30, 2024 | 196.47 Mn |
| Sep 30, 2024 | 196.47 Mn |
| Jun 30, 2024 | 64.40 Mn |
| Jun 30, 2024 | 64.40 Mn |
| Mar 31, 2024 | 64.20 Mn |
| Mar 31, 2024 | 64.20 Mn |
| Dec 31, 2023 | 192.70 Mn |
| Dec 31, 2023 | 192.70 Mn |
| Sep 30, 2023 | 176.13 Mn |
| Sep 30, 2023 | 176.13 Mn |